infectious-diseases-2018-posters-abstracts

19 / 35

Infectious Diseases 2018 Journal of Prevention and Infection Control
ISSN: 2471-9668 Page 58
June 07-08, 2018
London, UK
8th Edition of International Conference on
Infectious Diseases
Introduction: Drug-resistant tuberculosis (DR-TB) is a global
public health crisis. According to Global Tuberculosis report 2017,
treatment success rates of multi-drug-resistant tuberculosis
(MDR-TB) and extensively drug-resistant TB (XDR-TB) patients
are 46% and 29%. Henceforth one of the major obstacles in
achieving successful treatment outcomes in DR-TB is adverse
events affecting the adherence to the both first-line and second-
line drugs.
Aim: To evaluate the frequency of adverse events due to the
second-line drugs in MDR-TB patients during intensive phase of
treatment.
Settings & Design: A prospective cohort study was conducted
at DOTS Plus site at AIIMS, New Delhi. 81 consecutive MDR-
TB patients were recruited from June 2014 to May 2015 and
were given standardized revised national control tuberculosis
programme (RNCTP) drug-regimen. Patients were followed-up
during intensive phase of treatment and adverse events were
primarily recognized with clinical evidence and/or laboratory
investigations.
Results: A total of 91 adverse events were reported in 52 (64.1%)
patients. Only 1.2% of the patient stopped treatment and 9.8%
required removal of the suspected drug(s) from the regimen
due to adverse events. The grouped adverse events were most
commonly gastrointestinal (70.6%), arthralgia (10.9%), ototoxicity
(6.4%), psychiatric (5.5%), and hypothyroidism (2.1%). Nine (11%)
patients had serious adverse events requiring discontinuation or
substitution of drugs that included psychiatric disturbances in
6(7.4%) followed by hearing loss and tinnitus in 3(3.7%).
Conclusions: In India, programmatic management of drug
resistance tuberculosis guidelines (PMDT) provides guidance for
management of DR-TB but cure rate are undesirable and one of
the major issue to be catered is adherence which can assure for
successful treatment outcomes.
Adverse events in patients with multi drug resistant
tuberculosis: results of a prospective cohort study at tertiary
care level
Gupta G, Sharma S K, Sinha S,Soneja M and Jorwal P
All India Institute of Medical Sciences, India
J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003